ISTA Pharmaceuticals, Inc., a pharmaceutical company, discovers, develops, and markets remedies for diseases and conditions of the eye in the United States. It provides products to treat diseases of the eye and allergies; and therapies for ocular inflammation and pain, glaucoma, dry eye, and ocular and nasal allergies. The company offers Xibrom for the treatment of ocular inflammation and pain following cataract surgery; Bepreve to treat ocular itching associated with allergic conjunctivitis; Istalol for the treatment of Glaucoma; and Vitrase for use as a spreading agent. Its products under development include XiDay, which completed Phase III confirmatory clinical study for the treatment of ocular inflammation and pain following cataract surgery; T-Pred that completed Phase III bioequivalence study for the treatment of steroid-responsive inflammatory ocular conditions; Bromfenac lower concentration, which completed Phase II study to treat dry eye syndrome; Ecabet Sodium, a Phase IIb product for the treatment of dry eye syndrome; and Bepotastine Nasal to treat allergic rhinitis. The companys products under development also comprise a steroid product candidate to treat ocular inflammation; iganidipine to enhance ocular nerve blood flow; and a formulation of latanoprost, a prostaglandin, for the treatment of glaucoma. ISTA Pharmaceuticals, Inc. sells its products primarily to drug wholesalers, retailers, and distributors, including large chain drug stores, hospitals, clinics, government agencies, and managed healthcare providers. The company was formerly known as Advanced Corneal Systems, Inc. and changed its name to ISTA Pharmaceuticals, Inc. in March 2000. ISTA Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Irvine, California.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• No BuyIns.Net Alerts Available for ISTA